This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis

< Back

Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis


Skin Disease, Burns and Wound Care

May 2018

Atopic dermatitis (AD) or atopic eczema is a very common skin condition due to skin inflammation. It is usually a long-term condition where the skin becomes itchy, dry, cracked, sore and red. About one in every five children in the UK have AD. This condition may have impacts on the affected child’s quality of life. AD cannot be cured although it can improve significantly, or even clear completely, in some children as they get older. There is an unmet need for safe and effective long-term treatment for moderate-to-severe AD particularly in children.
Dupilumab is a monoclonal antibody medicine that is currently in development as an injection under the skin (subcutaneous) for the treatment of moderate to severe AD in children. Dupilumab is already licensed in the UK for the treatment of moderate-to-severe atopic dermatitis in adults. If licensed, dupilumab will offer an additional treatment option for children aged 12 years to 17 years with moderate to severe atopic dermatitis uncontrolled on current therapies.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts